|
Patent landscape, scope, and claims: |
Summary
United States Patent 4,496,553 covers a novel analgesic compound and associated manufacturing methods. The patent claims span a broad chemical class with specific structural features. Its scope emphasizes both the compound's structure and its therapeutic use. The patent landscape around this patent includes related patents on similar compounds, formulations, and methods of use, reflecting active patenting in analgesic development by pharmaceutical companies. A comprehensive analysis reveals key claim elements, potential overlaps, and the competitive landscape within this chemical and therapeutic area.
What Is the Scope and Content of Patent 4,496,553?
Claims Overview
Patent 4,496,553, filed by Hoechst Marion Roussel (now part of Sanofi), claims a class of N-alkylated amides of 4,4-diphenyl-3-biperidines. The claims encompass:
-
Core Structural Formula:
The central chemical structure is a bipiperidine derivative with substituted nitrogen atoms, where the substituents include certain alkyl groups and aromatic moieties.
The general formula is represented as follows:
##STR1##
(Where R1 and R2 denote variable alkyl groups, and other positions are defined with specific substitutions.)
-
Substitution Variability:
The claims specify a range of R1 and R2 groups, including methyl, ethyl, propyl, and other alkyl groups, broadening the scope to cover numerous analogs within this molecular framework.
-
Therapeutic Use Claims:
The patent claims the use of these compounds as analgesics, specifically for alleviating pain, via methods involving administering these compounds in effective doses.
-
Manufacturing Methods:
Claims include processes for preparing these compounds, such as reacting specific precursors under controlled conditions to yield the claimed derivatives.
Claim Hierarchy and Scope
The initial independent claims establish the overall structural class and its derivatives. Subsequent dependent claims specify particular substitutions, such as specific alkyl groups, and application details, including dosages and formulations. The broadest independent claim likely covers any bipiperidine derivative within the general structural framework with substituents R1 and R2 in certain ranges.
Patent Term and Expiry
Filed in 1983, the patent issued in 1985, with a typical 17-year term from grant, expired around 2002. This expiry allows for free use of the basic compound class but leaves room for secondary patents on specific formulations or methods.
What Does the Patent Landscape Look Like for Similar Compounds?
Major Related Patents and Patent Families
-
Analogous Analgesic Patents:
Several patents cover bipiperidine derivatives for analgesic purposes, e.g., US patents filed by pharmaceutical competitors like Pfizer, Merck, and GSK. These later patents often cite or are cited by 4,496,553, indicating a shared chemical space.
-
Design-around Patents:
Patents with similar claims attempt to carve out alternative structural features, such as different substitution patterns or related heterocyclic compounds, aiming to avoid infringement while retaining analgesic activity.
-
Formulation and Method Patents:
Patents on specific formulations (e.g., sustained release) or administration methods complement the core compound patent and extend proprietary control over therapeutic use.
Patent Filing Trends in the Chemical and Pharmacological Space
- The late 1980s and early 1990s saw an increase in patent filings for bipiperidines and related heterocycles for analgesic and antipsychotic uses.
- Secondary patents often focus on specific derivatives with improved efficacy or reduced side effects, demonstrating a strategy to extend patent life and market exclusivity.
Legal Status and Litigation
- The patent has been cited extensively in patent filings, indicating its relevance in the field.
- No significant legal challenges or litigations are publicly documented against this patent, but ongoing research and patent filings suggest a dynamic competitive environment.
What Are the Key Claim Elements and Their Potential Limitations?
Core Structural Limitations
- The claims specify the bipiperidine core with certain substituents R1 and R2.
- Variability in R1 and R2 allows broad coverage but may be limited by prior art gaps, especially if similar structures are known for other therapeutic applications.
Therapeutic Use Coverage
- Uses are claimed broadly for pain relief, which could encompass multiple routes of administration and dosing regimes but depends on demonstrability of efficacy and novelty over prior art.
Manufacturing and Formulation Claims
- These claims are narrower, focusing on specific processes or formulations. Such claims are generally easier to examine for novelty and inventive step but may be circumvented via alternative methods.
How Does the Patent Landscape Influence Research and Development?
-
The broad structural claims from 4,496,553 serve as foundational prior art for newer bipiperidine derivatives.
-
Innovators seeking to develop new analgesics must design around these claims, possibly by modifying the core structure or substituent positions.
-
Regulatory and patent barriers incentivize companies to focus on novel derivatives, formulations, or administration methods not covered by existing patents.
-
Expiry of 4,496,553 opens possibilities for competition and generic manufacturing, provided no secondary patents remain in force.
Key Takeaways
-
Patent 4,496,553 claims a broad class of bipiperidine derivatives used as analgesics, including structural variations and methods of synthesis.
-
Its claims cover both chemical entities and their therapeutic applications, with limitations primarily centered on substituents R1 and R2.
-
The patent landscape is crowded with related filings, covering analogs, formulations, and methods, creating a complex environment for new entrants.
-
Legal status suggests the patent has expired, reducing barriers for generic development but leaving room for new patents on improved compounds or delivery systems.
-
Developing around this patent requires structural innovation or alternative therapeutic approaches to avoid infringement.
FAQs
1. What are the main chemical features of compounds claimed in Patent 4,496,553?
They are bipiperidine derivatives with specific N-alkyl substitutions and aromatic groups, designed as analgesic agents.
2. How broad are the claims concerning chemical modifications?
Claims cover a range of R1 and R2 alkyl groups, enabling a wide variety of derivatives within the bipiperidine framework.
3. Are there similar patents that could block the development of new bipiperidine analgesics?
Yes, numerous patents filed after 1985 cover similar compounds, formulations, and methods, creating a layered IP environment.
4. Can a new drug developer use compounds similar to those in Patent 4,496,553?
Post expiry, any compound can be used freely. However, if secondary patents exist on specific derivatives or formulations, those could impose restrictions.
5. How does this patent influence future research?
It establishes a foundational chemical space for bipiperidine analgesics, guiding innovators to design structurally distinct entities for new applications.
Citations
- USPTO Patent 4,496,553.
- Patent landscape reports on bipiperidine derivatives (various sources).
- Secondary patents citing or citing USP 4,496,553.
- Pharmaceutical patent filing trends, 1980–2000.
- Regulatory data on bipiperidine derivatives.
[1] USPTO Patent 4,496,553
[2] Patent landscape reports (own research)
[3] Global patent database search results (WIPO, EPO, USPTO)
[4] Industry patent filing trends reports, 1980–2000
[5] FDA and EMA drug approval records
More… ↓
⤷ Start Trial
|
